ResMed
RMD
Market cap $37.3B

254.11 USD

-0.29

0.11%

At close Jul 14, 4:00 PM EDT

After hours

254.11

+0.00

0.00%

1 day

-0.11%

5 days

-0.77%

1 month

0.97%

3 months

18.45%

6 months

11.05%

Year to date

11.22%

1 year

23.77%

5 years

30.29%

10 years

341.32%

About: ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Employees: 9,980

Healthcare Medical Instruments & Supplies

0

Funds holding %

of 7,315 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

26% more first-time investments, than exits

New positions opened: 106 | Existing positions closed: 84

20% more repeat investments, than reductions

Existing positions increased: 340 | Existing positions reduced: 283

1.92% more ownership

Funds ownership: 61.34% [Q4 2024] → 63.27% (+1.92%) [Q1 2025]

1% more capital invested

Capital invested by funds: $20.6B [Q4 2024] → $20.8B (+$177M) [Q1 2025]

1% more funds holding

Funds holding: 855 [Q4 2024] → 862 (+7) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 7 [Q4 2024] → 7 (+0) [Q1 2025]

65% less call options, than puts

Call options by funds: $118M | Put options by funds: $340M

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$248

2%

downside

Avg. target

$270

6%

upside

High target

$290

14%

upside

6 analyst ratings

4 positive

67%

2 neutral

33%

0 negative

0%

RBC Capital Craig Wong-Pan	0%upside $255	Sector Perform Maintained	24 Apr 2025
UBS Laura Sutcliffe	12%upside $285	Buy Maintained	24 Apr 2025
JP Morgan David Low	14%upside $290	Overweight Maintained	24 Apr 2025
Piper Sandler Adam Maeder	2%downside $248	Neutral Maintained	24 Apr 2025
Keybanc Brett Fishbin	8%upside $274	Overweight Maintained	24 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about RMD published over the past 30 days

Top 15 High-Growth Dividend Stocks For July 2025

My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in June, gaining 6.15% versus SPY's 5.14% and VIG's 3.41%. The list's year-to-date return is 12.59%, beating SPY every month in 2025, though still a bit short of my 12% annualized target. The July 2025 Top 15 stocks offer a 1.38% average dividend yield with an 18.78% 5-year dividend growth rate and are 23% undervalued.

Top 15 High-Growth Dividend Stocks For July 2025

Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025

SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, July 31, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025

Zacks Investment Research

All You Need to Know About ResMed (RMD) Rating Upgrade to Buy

ResMed (RMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About ResMed (RMD) Rating Upgrade to Buy

Zacks Investment Research

Scoop Up These 4 GARP Stocks to Receive Handsome Returns

The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. SFM, ADBE, GE and RMD are some such stocks.

Scoop Up These 4 GARP Stocks to Receive Handsome Returns

The Motley Fool

ResMed: A Mixed Bag for Investors Amid Rising Competition

Explore the exciting world of ResMed (RMD 0.64%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

ResMed: A Mixed Bag for Investors Amid Rising Competition

ResMed: A Sleeping Giant Hiding In Plain Sight

ResMed dominates an enormous, underdiagnosed market with recurring revenue and digital health leadership, yet trades below its historical earnings multiples, offering compelling value. The company's sticky, essential products and expanding digital platform create a powerful, recession-resistant business model with strong secular tailwinds. We forecast 10% compound annual growth through 2030, with shares offering 13-21% upside based on reasonable valuation multiples and robust earnings growth.

ResMed: A Sleeping Giant Hiding In Plain Sight

Zacks Investment Research

ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy?

Top 15 High-Growth Dividend Stocks For June 2025

My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in May, gaining 6.45% versus SPY's 6.28% and VIG's 3.61%. The list's year-to-date return is 6.07%, beating SPY every month in 2025, though still short of my 12% annualized target. The June 2025 Top 15 stocks offer a 1.34% average dividend yield with a 22.82% 5-year dividend growth rate and are 25% undervalued.

Top 15 High-Growth Dividend Stocks For June 2025

Zacks Investment Research

ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue?

ResMed (RMD) reported earnings 30 days ago. What's next for the stock?

ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue?

Zacks Investment Research

Is it Worth Retaining ResMed Stock in Your Portfolio Now?

RMD gains on strong mask sales and digital health growth, but faces macro headwinds and fierce competition.

Is it Worth Retaining ResMed Stock in Your Portfolio Now?

See News Rankings

Charts implemented using Lightweight Charts™